ÂÜÀòÂÒÂ×

Lindsay Garrenton is a highly experienced scientist with expertise in cellular pharmacology, cancer targets, and immuno-oncology. Currently serving as Principal Scientist and Group Leader at Merck, Lindsay has previously held significant roles including Associate Director at REVOLUTION Medicines, where contributions included leading a team for pharmacogenomic screening and optimizing cellular screening strategies. Lindsay's career began with a post-doctoral research position at the University of California, followed by various positions at notable organizations including Five Prime Therapeutics, Elan Pharmaceuticals, Genentech, and Cytokinetics, focusing on assay development and target validation across multiple therapeutic areas. Lindsay holds a Ph.D. in Cell and Molecular Biology from the University of California, Berkeley, and an A.B. in Molecular Biology from Princeton University.